VG2025

DRUG4 trials

Sponsors

Virogin Biotech Canada Ltd, M.D. Anderson Cancer Center, Akeso, Virogin Biotech Ltd.

Conditions

Advanced Solid TumorCarcinomatosisColorectal Cancer With Hepatic MetastasesIntrahepatic CholangiocarcinomaSolid Tumor

Phase 1

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

RecruitingNCT05266612

Virogin Biotech Canada LtdSolid Tumor

Start: 2022-11-09End: 2025-12-31Target: 12Updated: 2024-08-09

Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis

WithdrawnNCT06365918

M.D. Anderson Cancer CenterAdvanced Solid Tumor, Carcinomatosis

Start: 2024-09-30End: 2024-10-02Updated: 2025-02-17

A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases

Not yet recruitingNCT07357220

AkesoColorectal Cancer With Hepatic Metastases

Start: 2026-03-02End: 2028-02-28Target: 72Updated: 2026-01-21

Phase 2

A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma

Not yet recruitingNCT07522476

Virogin Biotech Ltd.Intrahepatic Cholangiocarcinoma

Start: 2026-07-01End: 2028-11-13Target: 30Updated: 2026-04-13

Related Papers

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-012 citations